Allogeneic Cell-Mediated Immunotherapy at the Stage of Minimal Residual Disease following High-Dose Chemotherapy Supported by Autologous Stem Cell Transplantation
Author:
Publisher
S. Karger AG
Subject
Hematology,General Medicine
Reference35 articles.
1. Use of recombinant human interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematologic disorders
2. Immunotherapy With Recombinant Human Interleukin-2 and Recombinant Interferon-α in Lymphoma Patients Postautologous Marrow or Stem Cell Transplantation
Cited by 14 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Immunotherapy with cure potential of multi-drug resistant hematologic malignancies using IL-2 preactivated intentionally mismatched donor lymphocyte;Journal of Cancer Research and Clinical Oncology;2023-05-19
2. Immunotherapy of multi-drug resistant hematologic malignancies with IL-2-activated intentionally mismatched lymphocytes;2022-11-03
3. Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers;Current Drug Targets;2017-01-24
4. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation;Leukemia;2016-08-01
5. Harnessing the power of alloreactivity without triggering graft-versus-host disease: how non-engrafting alloreactive cellular therapy might change the landscape of acute myeloid leukemia treatment;Blood Reviews;2014-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3